

A Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study Evaluating the Safety, Pharmacokinetics and Clinical Benefit of FLUIGIV in Hospitalized Patients with Serious Influenza A Infection
Physician
Mohamed Turki, MD
Close
Synopsis:
The primary objective is to determine the optimal dose of FLUIGIV based upon evaluation of safety and pharmacokinetics (PK) in hospitalized patients with serious illness caused by laboratory-confirmed influenza A infection. The secondary objective is to evaluate the clinical benefit of FLU-IGIV in hospitalized patients with serious illness caused by laboratory-confirmed influenza A infection.
Close
Close
Close
Interested in a
Clinical Trial?